-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2085 A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Lymphomas, Clinical Research, Diseases, Aggressive lymphoma, Lymphoid Malignancies, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Naseem S. Esteghamat, MD1,2, Joseph M Tuscano, MD1, Brian A. Jonas, MD, PhD3, Aaron S. Rosenberg, MD4, Rasmus T. Hoeg, MD5*, Francisco Andres Socola, MD1, Brian Fury6*, Jordan Pavlic, MA7*, Geralyn Annett8*, Jan A. Nolta, PhD9* and Mehrdad Abedi, MD10*

1Department of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California, Davis Medical Center Comprehensive Cancer Center, Sacramento, CA
2UC Davis Comprehensive Cancer Center, Sacramento
3UC Davis Comprehensive Cancer Center, Davis, CA
4UC Davis Comprehensive Cancer Center, Sacramento, CA
5Comprehensive Cancer Center, University of California, Davis, Sacramento, CA
6UC Davis GMP Facility, Sacramento
7University of California, Davis Graduate Group in Immunology, GMP Facility, Sacramento, CA
8Department of Internal Medicine, University of California, Davis, Sacramento, CA
9University of California, Davis, Sacramento, CA
10University of California Davis, Sacramento, CA

Introduction: CD19 chimeric antigen receptor (CAR) T-cells have transformed the landscape of treatment for relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL); however, only ~40% of patients have durable responses (Neelapu 2023). Essential to a favorable environment for CAR T-cells to expand, exert anti-tumor activity, and persist is lymphodepleting chemotherapy. Cyclophosphamide and fludarabine is a frequently used combination of lymphodepletion; however, the dosing of these agents varies and there is limited data prospectively comparing these doses with efficacy and safety. Rituximab has also demonstrated synergism with CAR T-cells in pre-clinical models and is also believed to mediate peripheral B-cell depletion, facilitating better tumor targeting by CARs, but it’s role in lymphodepletion is not well described. In addition, timely access to this potentially curable therapy remains a challenge. As such, point of care manufacturing with rapid vein-to-vein time is critical to expanding access to CAR T-cell therapy.

Methods: This is a phase I, single-center 3+3 dose escalation study of locally manufactured CD19 CAR T-cells at our university’s GMP facility. The primary objectives include feasibility of manufacturing CD19 CAR T-cells, safety of escalating doses of lymphodepleting chemotherapy with or without rituximab, and safety of CD19 CAR T-cells in subjects with R/R DLBCL. Overall response rate (ORR), complete response (CR), partial response (PR), progression free survival (PFS), and overall survival (OS) are secondary objectives. This is an autologous CD19-directed CAR created with a lentiviral vector (Miltenyi Biotec), a 4-1BB costimulatory domain, and a CD3 zeta intracellular domain. Patients with R/R DLBCL after > 2 prior lines of therapy are eligible. Subjects receive escalating doses of lymphodepleting chemotherapy with cyclophosphamide and fludarabine with or without rituximab in 6 dose levels (DL). The fludarabine dose remains constant at 25 mg/m2 Days -5 to -3, and the cyclophosphamide dose escalates from 500 mg/m2 x 3 doses in DL 1 and 2, to 60 mg/kg x 1 dose in DL 3 and 4, and to 60 mg/kg x 2 doses in DL 5 and 6. Rituximab is given in DL 2, 4, and 6. A CAR T-cell dose of 1x106 cells/kg is given in each DL. The CAR T-cells were initially harvested at Day 12 then thawed from a cryopreserved product; they are currently given as a fresh infusion after an 8-day manufacturing period.

Results: At time of data cutoff, 20 subjects enrolled and 15 are evaluable: 3 on DL 1, 4 on DL 2, 5 on DL 3, and 3 on DL 4. 6 patients have received fresh cell infusion since the manufacturing time was shortened. 11 (73%) subjects are female; median age is 63 (range 28-77). 9 subjects (60%) had primary refractory disease; 5 (33.3%) relapsed > 12 months from initial therapy and 1 (6.7%) relapsed < 12 months from initial therapy. 2 subjects had double hit lymphoma, 4 were double expressors, and 3 transformed from follicular lymphoma. 5 subjects have GCB immunophenotype, 8 have non-GCB, and 2 are unknown. Stage of disease includes 3 subjects with stage 2, 2 with stage 3, and 10 with stage IV. The median number of prior lines of therapy is 3 (range 2-8). 5 subjects had prior autologous stem cell transplantation (SCT) and 1 had prior allogeneic SCT.

Day +30 PET shows ORR 86% (13/15), CR 46.7% (7/15), and PR 40% (6/15). On Day +90 PET, 3 additional subjects converted to CR (10/15; 67.7%); 2 subjects received no additional therapy and 1 started lenalidomide between Day +30 and +90. The median follow-up time is 9 months. At time of data cutoff (30 months; July 21, 2024), PFS is 67.7% (10/15) and OS 73.3% (11/15). 4 patients have expired: 3 from disease progression and 1 from infection. 6 subjects (40%) experienced CRS, with 4 (26.7%) Grade 1 events in DL 2, 3, and 4, and 2 (13.3%) Grade 2 events in DL 2 and 3. 1 subject (6.7%) had Grade 2 ICANS in DL 3. There have been no Grade 3 or 4 CRS or ICANS events. There are no dose limiting toxicities to date.

Conclusions: These results demonstrate the safety and efficacy of CD19 CAR T-cells with escalating doses of lymphodepleting cyclophosphamide and fludarabine with and without rituximab. There have been no dose limiting toxicities and no Grade 3-4 CRS or ICANS. The feasibility of point of care manufacturing with vein-to-vein time of 8 days is demonstrated in this phase I study. The efficacy of the CARs is maintained and comparable to commercial CD19 products without any severe CRS or ICANS. Enrollment continues on DL 5.

Disclosures: Esteghamat: Seagen: Ended employment in the past 24 months, Speakers Bureau. Jonas: Jazz: Research Funding; Loxo Oncology: Research Funding; Incyte: Research Funding; Immune-Onc: Research Funding; Hanmi: Research Funding; Forty-Seven: Research Funding; Forma Therapeutics: Research Funding; F. Hoffman-La Roche: Research Funding; Celgene: Research Funding; Aptose: Research Funding; AROG: Research Funding; Amgen: Research Funding; Rigel: Consultancy, Other: Travel; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kymera: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlycoMimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding; Treadwell: Research Funding. Rosenberg: BMS: Consultancy; Biomea: Research Funding; Kangpu Pharmaceuticals: Research Funding; Pfizer: Consultancy; Sanofi: Membership on an entity's Board of Directors or advisory committees. Hoeg: Orca Bio: Research Funding. Abedi: CytoDyn: Current holder of stock options in a privately-held company; AbbVie, BMS and Gilead Sciences: Speakers Bureau; Autolus, BMS and Gilead Sciences: Research Funding; BMS, Autolus: Consultancy; Orca Bio: Research Funding.

*signifies non-member of ASH